Učitavanje...
Cardiovascular toxicity following anti-angiogenic therapy in persons over age 65 with advanced renal cell carcinoma
BACKGROUND: Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of patients with renal cell carcinoma (RCC) in 2005-2006. We conducted a population-based observational cohort study on the cardiovascular risk of...
Spremljeno u:
| Izdano u: | Cancer |
|---|---|
| Glavni autori: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4602387/ https://ncbi.nlm.nih.gov/pubmed/26439451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29728 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|